U.S. Building Stock News

If you are wondering whether DigitalOcean Holdings is still attractively priced after its recent run, you are not alone. This article will help you weigh what the current share price really reflects. The stock most recently closed at US$56.06, with returns of 1.5% over the last 30 days, 14.5% year to date, and 30.8% over the past year. The last 7 days showed an 11.9% decline that may have changed how some investors see the risk and reward trade off. Recent news coverage has focused on...

Gulfport Energy (GPOR) just posted fourth quarter and full year 2025 results, reporting a move from prior losses to profit along with higher revenue, and also provided updated production guidance and an expanded share repurchase plan. See our latest analysis for Gulfport Energy. At a share price of US$208.66, Gulfport Energy has seen a 3.30% 1 day share price return and a 2.20% 30 day share price return, but a 5.92% 90 day share price decline. The 1 year total shareholder return of 22.89% and...

Buenaventura (NYSE:BVN) has approved a higher dividend payout policy, supported by strong operating cash flow. The Board also cleared a higher dividend distribution to shareholders under the new framework. The San Gabriel project is approaching completion, with ramp up reported as close to finished. For you as an investor, the combination of a higher dividend payout policy and a near complete San Gabriel ramp up is a key development for Compañía de Minas Buenaventura, a precious metals...

Without a clear single news event driving headlines, National Health Investors (NHI) has still drawn attention as investors review its recent share performance and financial profile in the senior housing and healthcare real estate space. See our latest analysis for National Health Investors. The recent 4.1% one-day share price decline to about $84.07 follows a 7.4% 90-day share price return and a 23.1% 1-year total shareholder return. This suggests longer-term momentum, although very...

In late February 2026, Opera Limited reported past fourth-quarter 2025 revenue of US$177.21 million and net income of US$55.71 million, alongside full-year 2025 revenue of US$614.83 million and a new two-year, US$300 million share repurchase authorization funded from its operating cash and balance sheet. The combination of higher earnings per share, upbeat 2026 revenue guidance, and a large buyback program underscores Opera’s confidence in its cash generation and the long-term importance of...

If you are wondering whether OGE Energy is still fairly priced after its recent run, or if the current share price is giving you a margin of safety, this article walks through what the numbers say about value. With the stock at US$49.14 and returns of 3.8% over 7 days, 12.5% over 30 days, 14.6% year to date, 10.3% over 1 year, 56.3% over 3 years and 93.0% over 5 years, many investors are asking whether the current price still makes sense. Recent attention on OGE Energy has focused on how a...

If you are wondering whether LegalZoom.com’s current share price reflects its true worth, you are not alone. This article focuses on what the numbers say about value. The stock last closed at US$7.03, with a 7 day return of 7.2%, but declines of 20.9% over 30 days, 26.7% year to date, and 30.8% over the past year. These moves have put valuation questions front and center for many investors, who are weighing short term swings against the longer term picture. Evergreen coverage like this aims...

PTC Therapeutics (PTCT) shares are in focus after the company released fourth quarter and full year 2025 results, which combined weaker quarterly figures with a sharp full year swing to positive earnings. See our latest analysis for PTC Therapeutics. At a share price of US$68.19, PTC Therapeutics has recently seen weaker short term share price returns, with a 30 day share price return of 9.72% and a year to date share price return of 11.14%. Its 1 year total shareholder return of 23.4% and 3...

Fulton Financial (FULT) is back on investor radars after a recent share pullback, with the stock closing at US$20.45. That is shifting sentiment toward its valuation and the bank’s underlying financial profile. See our latest analysis for Fulton Financial. The recent 5.5% one day share price decline and 8.7% 7 day share price return dip sit against a 90 day share price return of 11.2% and 1 year total shareholder return of 7.3%. This suggests that longer term momentum is still intact despite...

In recent months, BankUnited reported solid quarterly results and continued investments in digital capabilities and new markets, even as its net interest income growth trailed the broader banking industry and analysts projected a weaker efficiency ratio ahead. This tension between operational expansion and concerns about slowing profitability has led some analysts to question how durable BankUnited’s current growth ambitions may be. Next, we’ll examine how these concerns about slowing net...

Dell Technologies (NYSE:DELL) reported record financial results, supported by a $43b AI server backlog. The company set ambitious AI growth targets and announced a $10b increase to its share repurchase authorization. Dell raised its dividend by 20% and introduced the rugged, liquid cooled PowerEdge XR9700 server for edge AI workloads. The company expanded partnerships, including a deeper alliance with Unisys and an extended collaboration with McLaren Racing in Formula 1. For investors...

Coterra Energy (CTRA) has drawn fresh attention after recent share price moves, with the stock up around 6% over the past month and about 13% over the past 3 months. See our latest analysis for Coterra Energy. Viewed over a longer stretch, Coterra Energy’s recent 1 day share price return of 1.93% sits within a broader pattern that includes a 30 day share price return of 6.03%, a year to date share price return of 15.00%, and a 1 year total shareholder return of 17.32%. Together, these figures...

Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, highlighting progress across specialty, injectables, biosimilars, and complex generics. The company announced multiple product launches and regulatory approvals, expanding its presence in higher value segments. Management highlighted a promising pipeline, including biosimilars expected to enter the US market. Amneal also emphasized its collaboration with Pfizer on GLP-1 therapies as a key focus area for future...

Aurinia Pharmaceuticals reported strong commercial performance in LUPKYNIS, contributing to higher net income supported by a tax benefit. The company initiated a new clinical study of aritinercept for autoimmune diseases, expanding its development pipeline. A pediatric VOCAL study was terminated, and Aurinia is now working with regulators to address pediatric requirements. Aurinia Pharmaceuticals, listed as NasdaqGM:AUPH, is drawing attention after stronger LUPKYNIS sales and a tax benefit...

If you are wondering whether Home Depot at around US$380 is still a solid entry or starting to look expensive, you are not alone. The stock last closed at US$380.72, with returns of 1.6% over 30 days, 10.1% year to date and 69.6% over 5 years, while the 1 year return is a 1.6% decline and the 3 year return is 37.7%. Recent news coverage has focused on Home Depot's role as a bellwether for US housing and renovation trends, and what that might mean for longer term demand. At the same time,...

Caris Life Sciences (NasdaqGS:CAI) reported an interim readout from its Achieve 1 study for the Caris Detect multi cancer early detection blood test. The interim data show sensitivity and specificity that the company says outperform current methylation based approaches. Caris is adding Whole Transcriptome Sequencing to Caris Detect to deepen molecular resolution in the test. The company also introduced a new AI powered breast cancer signature in its Molecular Tumor Board Report to expand...

Eli Lilly and Incyte have received a positive opinion from the European Medicines Agency for Olumiant to treat adolescents with severe alopecia areata in Europe, marking a potential expansion of its approved uses. This regulatory progress highlights how broadening Olumiant’s eligible patient population could enhance the drug’s clinical relevance within Incyte’s immunology portfolio. We’ll now explore how this positive EMA opinion for adolescent alopecia areata may influence Incyte’s...

Hamilton Insurance Group (HG) is back on investors’ radar after reporting fourth quarter and full year 2025 results, declaring a special dividend of $2.00 per share and attracting renewed attention from Wall Street research desks. See our latest analysis for Hamilton Insurance Group. At a share price of $31.59, Hamilton Insurance Group has seen a 30 day share price return of 13.84% and a year to date share price return of 15.84%. The 1 year total shareholder return of 61.50% points to strong...

McDonald's (MCD) has put its new Big Arch Burger at the center of its latest U.S. menu push, using the limited time launch to test how a larger, higher priced item fits with its value reset. See our latest analysis for McDonald's. The new Big Arch launch comes as momentum in McDonald’s shares has been firm, with a 30 day share price return of 8.3% and a 1 year total shareholder return of 13.2%, building on a 5 year total shareholder return of 83.2%. If this kind of menu driven story has your...

EPR Properties recently reported its fourth-quarter and full-year 2025 results, showing higher revenue of US$182.95 million for the quarter and US$718.36 million for the year, a swing to quarterly net income of US$66.9 million, and announced a 5.1% increase in its annualized common dividend to US$3.72 per share alongside updated 2026 earnings guidance. The company also continued reshaping its business with additional experiential real estate acquisitions, new debt and equity financing...

Oncolytics Biotech (NasdaqCM:ONCY) has completed patient enrollment in its Phase 1/2 GOBLET study. The company is moving ahead with pivotal trials in squamous cell anal cancer and metastatic colorectal cancer. Management is shifting clinical focus and resources toward these rare cancer indications and planning FDA interactions related to potential approval pathways. Oncolytics Biotech focuses on cancer therapies, and the GOBLET study sits at the center of that effort. With enrollment now...

If you are wondering whether Synopsys at around US$414 a share still makes sense for your portfolio, starting with a clear view of what you are paying for is essential. The stock is currently below recent levels, with a 5.9% decline over the last 7 days, 11.0% over 30 days, a 13.8% decline year to date and a 9.5% decline over 1 year, while the 3 year and 5 year returns sit at 12.7% and 81.7% respectively. These moves have put valuation back in focus for many investors, especially given...

Daktronics (NasdaqGS:DAKT) has agreed to supply an integrated digital display system across the OCVIBE campus, a large mixed-use development project. The company also announced an executive leadership change, with the former Interim President and CEO moving into an advisory role. Both updates relate to Daktronics' positioning in large commercial installations and its ongoing leadership structure. Daktronics focuses on electronic scoreboards, digital signage, and large-format LED video...

In late February 2026, Pravati Capital announced a partnership with SEI Investments' SEI Access™ marketplace to make litigation finance available as an alternative investment option for registered investment advisors and financial professionals through an end-to-end platform. Around the same time, SEI reported quarterly revenue of US$607.9 million, up 9.1% year on year and slightly above analyst expectations, with management highlighting disciplined execution and broad-based strength across...